ApiFix

Company Overview

Snapshot

Founded in March 2011 by Yizhar Floman and Uri Arnin, ApiFix operates with 11–50 employees. The company raised $8 million across 3 funding rounds from 2 investors before being acquired by Orthopediatrics in April 2020.

Business overview

ApiFix develops a minimally invasive scoliosis correction system designed for patients with adolescent idiopathic scoliosis, specifically those classified as Lenke type 1 or type 5 with a Cobb angle of 40 to 60 degrees. Its core technology, the ApiFix Internal Brace System, involves a minimal surgical intervention followed by a multi-month correction process aided by physical therapy. This system utilizes an expandable rod with a miniature ratchet mechanism to achieve incremental deformity corrections. The company serves the healthcare industry, targeting clinics, hospitals, and healthcare providers with its medical products for pediatric patients.

Strategic signal

In August 2019, ApiFix received FDA approval via a humanitarian device exemption to commercialize its MID-C System for the treatment of progressive adolescent idiopathic scoliosis. This regulatory milestone was a significant validation of the company's technology, enabling market access in the United States and signaling strong potential for broader adoption of its motion-preserving deformity treatment.

Company Intelligence Q&A

When was ApiFix acquired and by whom?

ApiFix was acquired by Orthopediatrics in April 2020.

What was a significant regulatory achievement for ApiFix?

In August 2019, ApiFix received FDA approval to commercialize its MID-C System for the motion-preserving deformity treatment of progressive idiopathic scoliosis in adolescents.

Which investors participated in ApiFix's April 2019 funding round?

In April 2019, ApiFix received funding from The Trendlines Group and B. Braun Melsungen AG.

When did ApiFix announce new leadership?

ApiFix Ltd. announced new leadership in January 2018.

When did ApiFix complete its first cases in North America?

In September 2017, ApiFix completed its first cases in North America at IWK Health Centre Hospital in Halifax, Canada.